Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and nonsteroidal anti-inflammatory agents

Xenobiotica

Volumn 28, Issue 3, 1998, Pages 293-301

  Tassaneeyakul, W ^b   Birkett, D J ^a   Miners, J O ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; BIFONAZOLE; BROMAZEPAM; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LIVER ENZYME; MEFENAMIC ACID; MIANSERIN; MIDAZOLAM; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PIROXICAM; PYRROLE DERIVATIVE; SULINDAC; THIORIDAZINE; TOLMETIN; UNINDEXED DRUG;

ARTICLE; COMPETITIVE INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; INHIBITION KINETICS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIFUNGAL AGENTS; AZOLES; BENZODIAZEPINES; CYTOCHROME P-450 CYP2E1; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROSOMES, LIVER;

EID: 0031933926     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239579     Document Type: Article

References (27)

1. BACK, D. J., TJIA, J. F., KARBWANG, J. and COLBERT, J., 1988, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones. British Journal of Clinical Pharmacology, 26, 23-29.
2. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261-270.
3. GONZALEZ, F. J., 1992, Human cytochromes P450: problems and prospects. Trends in Pharmacological Sciences, 13, 346-352.
4. GRUENKE, L. D., KONOPKA, K., KOOP, D. R. and WASKELL, L., 1988, Characterisation of halothane oxidation by hepatic microsomes and purified cytochrome P450 using gas-chromatography mass spectrometric assay. Journal of Pharmacology and Experimental Therapeutics, 246, 454-459.
5. GUENGERICH, F. P., 1993, Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metabolism and Disposition, 21, 1-6.
6. GUENGERICH, F. P., KIM, D. H. and IWASAKI, M., 1991, Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
7. HA, H. R., CHEN, J., FREIBURGHAUS, A. U. and FOLLATH, F., 1995, Metabolism of theophylline by cDNA-expressed human cytochromes P450. British Journal of Clinical Pharmacology, 39, 321-326.
8. HARGREAVES, M. B., JONES, B. C., SMITH, D. A. and GESCHER, A., 1994, Inhibition of p-nitrophenol in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metabolism and Disposition, 22, 806-810.
9. HOLFORD, N. H. G., 1985, MKMODEL: a modelling tool for microcomputers. Clinical Experimental Pharmacology and Physiology, 9 (suppl.), 95.
10. KHARASCH, E. D. and THUMMEL, K. E., 1993, Identification of cytochrome P4502E1 as the predominant enzyme catalyzing human liver microsomal defluorimation of sevoflurane, isoflurane and methoxyflurane. Anesthesiology, 79, 795-807.
11. KOOP, D. R., 1992, Oxidative and reductive metabolism by cytochrome P4502E1. FASEB Journal, 6, 724-730.
12. KUNZE, K. L., WIENKERS, L. C., THUMMEL, K. E. and TRAGER, W. F., 1996, Warfarin-fluconazole I: inhibition of the human cytochrome P450 dependent metabolism of warfarin by fluconazole - in vitro studies. Drug Metabolism and Disposition, 24, 414-421.
13. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measured with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
14. MAURICE, M., PICHAHD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
15. MURRAY, M., 1987, Mechanisms of the inhibition of cytochrome P450 mediated drug oxidation by therapeutic agents. Drug Metabolism Reviews, 18, 55-81.
16. O'REILLY, R. A., GOULART, D. A., KUNZE, K. L., NEAL, J., GIBALDI, M., EDDY, A. C. and TRAGER, W. F., 1992, Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clinical Pharmacology and Therapeutics, 51, 656-667.
17. PATTEN, C. J., THOMAS, P. E., GUY, R. C., LEE, M., GONZALEZ, F. J., GUENGERICH, F. P. and YANG, C. S., 1993, Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chemical Research in Toxicology, 6, 511-518.
18. PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450 IIE1. Chemical Research in Toxicology, 3, 566-573.
19. ROBSON, R. A., MATTHEWS, A. P., MINERS, J. O., MCMANUS, M. E., MEYER, U. A., HALL, P. D. and BIRKETT, D. J., 1987, Characterisation of theophylline metabolism by human liver microsomes. British Journal of Clinical Pharmacology, 24, 293-300.
20. RODRIGUES, A. D., GIBSON, G. G., IOANNIDES, C. and PARKE, D. V., 1987, Interactions of imidazole antifungal agents with purified cytochrome P450 proteins. Biochemical Pharmacology, 36, 4277-4281.
21. SHEETS, J. J., MASON, J. I., WISE, C. A. and ESTABROOK, R. A., 1986, Inhibition of rat liver microsomal cytochrome P450 steroid hydroxylase reactions by imidazole antimycotic agents. Biochemical Pharmacology, 35, 487-491.
22. TASSANEEYAKUL, W., BIRKETT, D. J., EDWARDS, J. W., VERONESE, M. E., TASSANEEYAKUL, W., TUKEY, R. H. and MINERS, J. O., 1996, Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene. Journal of Pharmacology and Experimental Therapeutics, 276, 101-108.
23. TASSANEEYAKUL, W., BIRKETT, D. J., MCMANUS, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A4 isoforms. Biochemical Pharmacology, 47, 1767-1776.
24. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. and MINERS, J. O., 1993a, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA-expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975-1981.
25. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J. and MINERS, J. O., 1993b, High performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P4502E1 activity, by human liver microsomes. Journal of Chromatography, 616, 73-78.
26. THUMMEL, K. E., KHARASCH, E. D., PODOLL, T. and KUNZE, K., 1993, Human liver microsomal enflurane defluorination catalyzed by cytochrome P4502E1. Drug Metabolism and Disposition, 21, 350-357.
27. YANG, C. S., Yoo, J. H., ISHIZAKI, H. and HONG, J., 1990, Cytochrome P450 IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metabolism Reviews, 22, 147-157.